The U.S. Food and Drug Administration (FDA) is continuing its review of several widely discussed compounded peptides, signaling increased regulatory attention toward a category of therapies that has gained significant popularity in wellness, functional medicine, and longevity care.
Ahead of a scheduled July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff released briefing documents stating that the currently available evidence does not support allowing compounding pharmacies to use seven peptide substances in compounded medications.
Although the committee's recommendations are advisory rather than binding, they are expected to play an important role in shaping future FDA decisions.
Which Peptides Are Under Review?
The advisory committee will evaluate whether the following peptides should be included on the FDA's list of bulk drug substances that may be used in pharmacy compounding:
- BPC-157, commonly promoted for ulcerative colitis and tissue repair
- KPV, associated with wound healing and inflammatory conditions
- TB-500, often discussed for wound healing and recovery
- MOTS-c, promoted for obesity and osteoporosis
- Emideltide, proposed for opioid withdrawal and chronic insomnia
- Semax, promoted for conditions including cerebral ischemia, migraines, and chronic pain
- Epitalon, marketed for insomnia and longevity-related applications
These peptides have become increasingly visible in wellness and longevity discussions, despite varying levels of scientific evidence supporting many of their proposed uses.
FDA Staff Raise Concerns About Clinical Evidence
According to the FDA's briefing materials, reviewers found limited evidence demonstrating the effectiveness of these peptides for their proposed indications.
Among the agency's primary concerns are:
- A lack of well-designed human clinical trials
- Limited data supporting safety and effectiveness
- Questions regarding product quality and consistency
- Potential risks related to immunogenicity, toxicity, and impurities
FDA reviewers concluded that the currently available data do not provide sufficient support for compounding these substances for the indications under consideration.
Background on Peptide Compounding
Peptides are short chains of amino acids that play important roles throughout the body by acting as signaling molecules and supporting numerous biological processes.
Interest in peptide therapies has expanded rapidly in recent years, particularly within wellness, regenerative medicine, functional medicine, and longevity practices. Many peptides are promoted online for applications ranging from tissue repair and metabolic health to sleep and recovery.
However, not all peptide therapies have undergone the level of clinical testing typically required to establish safety and effectiveness for widespread medical use.
The FDA has previously expressed concerns about compounded peptides. In 2023, the agency cited safety risks, including immunogenicity, toxicity, and impurities, as reasons for limiting compounding of certain peptide substances.
Advisory Committee Recommendations Will Inform FDA Decisions
The upcoming Pharmacy Compounding Advisory Committee meeting will allow independent experts to review the available scientific evidence and discuss whether these peptide substances should be eligible for pharmacy compounding.
While the committee's recommendations are not legally binding, they often provide important guidance that informs the FDA's final regulatory decisions.
The FDA also recently announced several new members of the advisory committee, including individuals with experience in wellness clinics and organizations involved in peptide-related therapies.
What This Means for Healthcare Practices
Practices that incorporate peptide therapies or closely follow developments in compounded medications should monitor the outcome of the July advisory committee meeting.
Any future FDA decisions could affect:
- Availability of certain compounded peptides
- Pharmacy compounding practices
- Clinical protocols involving peptide therapies
- Regulatory compliance for providers offering peptide-based treatments
Healthcare providers should continue following current FDA guidance and rely on evidence-based clinical decision-making as additional regulatory updates become available.
Disclaimer: This article is intended for informational purposes only and should not be interpreted as legal, regulatory, or medical advice. Healthcare providers should consult current FDA guidance and applicable state regulations when making clinical or compounding decisions.
Source:
Reuters. (2026, June 30th). US FDA staff highlights peptide risks, says little evidence of benefits. Yahoo News. https://www.yahoo.com/news/science/articles/us-fda-staff-highlights-peptide-125317484.html
